Biotech Archives - Page 788 of 795

2 minute read

Can-Fite To Submit FDA & EMA Registration Plans For Piclidenoson In The Oral Treatment Of Moderate To Severe Psoriasis

July 11, 7:02 AM

Further analysis of Phase III COMFORT™ data show Piclidenoson's superior safety profile and higher patient compliance compared to Otezla® Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a

CANF

1 minute read

Patient Death Prompts MacroGenics To Close Mid-Stage Head & Cancer Study

By Vandana Singh

July 11, 6:40 AM

MacroGenics Inc (NASDAQ:MGNX) closed the Phase 2 study (CP-MGA271-06) of enoblituzumab in the first-line treatment of patients with recurrent or metastatic…

MGNX

2 minute read

FDA
News

Nyxoah Received FDA IDE Approval to Initiate the ACCCESS Study of Genio in Complete Concentric Collapse Patients

By Charles Gross

July 11, 5:46 AM

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the U.S.

NYXH

2 minute read

FDA
News

Macrogenics Announces Closure Of CP-MGA271-06 Study Evaluating Enoblituzumab Plus Checkpoint Inhibition In Head And Neck Cancer; Shares Move Sharply Lower

By Benzinga Newsdesk

July 8, 4:33 PM

MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of July 7,

MGNX

4 minute read

FDA
News

Apyx Medical Corporation Announces Results Of The U.S. Ide Clinical Study Evaluating The Use Of Renuvion To Improve The Appearance Of Lax Skin In The Neck And Submental Region; Says Primary Effectiveness Endpoint Of Study Was Met

By Benzinga Newsdesk

July 8, 3:54 PM

Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the results of

APYX

1 minute read

Raymond James Initiates Coverage On This Stock With Bullish Pitch On Gene Therapies

By Vandana Singh

July 8, 1:58 PM

Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs and LAD-I.

RCKT

2 minute read

Filament Begins First Ever FDA-Approved Clinical Trial On Naturally-Derived Psychedelic Drugs

By Lara Goldstein

July 8, 1:09 PM

Clinical-stage natural psychedelics company Filament Health Corp.

FLHLF

1 minute read

Needham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory Path

By Vandana Singh

July 8, 12:53 PM

Yesterday, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced data from the new interim analysis of the Phase 3 REGENERATE trial evaluating obeticholic acid in…

ICPT

1 minute read

Why This Small-Cap Stock Is Gaining More Than 10% Today?

By Vandana Singh

July 8, 11:40 AM

Chardan has initiated coverage of Immuneering Corp (NASDAQ:IMRX) with a Buy rating and a price target of $18. Immuneering’s lead candidate, IMM-1-104, an…

IMRX

1 minute read

FDA
News

NYC Healthy Tweets ‘We’re currently seeing high levels of COVID-19 in NYC. To help slow the spread, all New Yorkers should wear a high-quality mask, such as an N95, KN95 or KF94 in all public indoor settings and around crowds outside’

By Benzinga Newsdesk

July 8, 11:16 AM

https://twitter.com/nycHealthy/status/1545426238638067712

SPY